Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Author:
Affiliation:
1. Department of Haematology, St Vincent’s Hospital Melbourne, Fitzroy, Australia;
2. Baker IDI Heart and Diabetes Institute, Melbourne, Australia
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1375110
Reference86 articles.
1. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
2. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
3. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
4. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
5. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impaired Cardiac AMPK (5′‐Adenosine Monophosphate‐Activated Protein Kinase) and Ca 2+ ‐Handling, and Action Potential Duration Heterogeneity in Ibrutinib‐Induced Ventricular Arrhythmia Vulnerability;Journal of the American Heart Association;2024-06-18
2. Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database;Cardio-Oncology;2024-06-01
3. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024);CHINESE J CANCER RES;2024
4. A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score;Turkish Journal of Hematology;2024-05-30
5. Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies;World Journal of Cardiology;2024-05-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3